15mg tirzepatide vial – 60 mg Tirzepatide 15mg — 15mg/vial Reference

Cancer Cell 21 , 642654 (2012)

The duration of treatment is personalized based on your individual weight loss goals and progress

useful for upper GI targeting Troches buccal absorption, limited evidence specific to BPC-157 Who oral delivery is best suited for: Leaky gut / intestinal permeability Inflammatory bowel disease (IBD, Crohn's, ulcerative colitis) NSAID-induced gastric damage or ulcers Irritable bowel syndrome (IBS) General GI maintenance alongside other therapies Patients who cannot or will not self-inject Practical considerations: Oral bioavailability is lower for systemic goals do not expect injection-equivalent tendon or joint results Dosing protocols typically require three to ten times the injectable dose to achieve comparable GI effects Product quality varies widely in the oral supplement market sourcing from a licensed compounding pharmacy is essential Nasal BPC-157: Emerging Option, Limited Evidence Nasal BPC-157 is the third delivery route and the least established

The powerful supplement that optimizes fat metabolism and enhances energy production for improved performance

The best thing to do is to talk to your healthcare provider for advice just for you